Alterity Therapeutics Limited (ATH.AX)
AUD 0.01
(11.11%)
AUD 0.01
(11.11%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | -12.47 Million AUD | 19.81% |
| 2023 | -15.56 Million AUD | 55.13% |
| 2022 | -34.68 Million AUD | -23.67% |
| 2021 | -28.04 Million AUD | -206.12% |
| 2020 | -9.16 Million AUD | 36.37% |
| 2019 | -14.39 Million AUD | 5.48% |
| 2018 | -15.23 Million AUD | 30.38% |
| 2017 | -21.88 Million AUD | 23.46% |
| 2016 | -28.59 Million AUD | 18.09% |
| 2015 | -34.9 Million AUD | -2.17% |
| 2014 | -34.16 Million AUD | -172.37% |
| 2013 | -12.54 Million AUD | -135.02% |
| 2012 | -5.33 Million AUD | 37.59% |
| 2011 | -8.55 Million AUD | -63.61% |
| 2010 | -5.22 Million AUD | -21.42% |
| 2009 | -4.3 Million AUD | 61.71% |
| 2008 | -11.24 Million AUD | -51.78% |
| 2007 | -7.4 Million AUD | 26.07% |
| 2006 | -10.01 Million AUD | 53.1% |
| 2005 | -21.36 Million AUD | 27.33% |
| 2004 | -29.4 Million AUD | -751.33% |
| 2003 | -3.45 Million AUD | 3.72% |
| 2002 | -3.58 Million AUD | 47.67% |
| 2001 | -6.85 Million AUD | -53.37% |
| 2000 | -4.46 Million AUD | -22347845.0% |
| 1999 | -20.00 AUD | 0.0% |
| 1998 | -20.00 AUD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -12.24 Million AUD | 0.0% |
| 2024 Q4 | -12.47 Million AUD | 0.0% |
| 2024 FY | -12.47 Million AUD | 19.81% |
| 2023 FY | -15.56 Million AUD | 55.13% |
| 2023 Q4 | -15.56 Million AUD | 0.0% |
| 2023 Q2 | -25.3 Million AUD | 0.0% |
| 2022 Q2 | -36.96 Million AUD | 0.0% |
| 2022 FY | -34.68 Million AUD | -23.67% |
| 2022 Q4 | -34.68 Million AUD | 0.0% |
| 2021 FY | -28.04 Million AUD | -206.12% |
| 2021 Q4 | -28.04 Million AUD | 0.0% |
| 2021 Q2 | -35.04 Million AUD | 0.0% |
| 2020 Q2 | -12.17 Million AUD | 0.0% |
| 2020 Q3 | -9.19 Million AUD | 24.48% |
| 2020 Q4 | -9.16 Million AUD | 0.37% |
| 2020 FY | -9.16 Million AUD | 36.37% |
| 2020 Q1 | -12.17 Million AUD | 15.43% |
| 2019 Q1 | -8.38 Million AUD | 44.98% |
| 2019 Q3 | -14.39 Million AUD | -71.77% |
| 2019 Q2 | -8.38 Million AUD | -0.0% |
| 2019 FY | -14.39 Million AUD | 5.48% |
| 2019 Q4 | -14.39 Million AUD | 0.0% |
| 2018 Q3 | -15.23 Million AUD | 23.48% |
| 2018 Q2 | -19.91 Million AUD | 0.0% |
| 2018 Q1 | -19.91 Million AUD | 9.02% |
| 2018 FY | -15.23 Million AUD | 30.38% |
| 2018 Q4 | -15.23 Million AUD | 0.0% |
| 2017 Q1 | -28.34 Million AUD | 0.88% |
| 2017 Q2 | -28.34 Million AUD | 0.0% |
| 2017 FY | -21.88 Million AUD | 23.46% |
| 2017 Q4 | -21.88 Million AUD | 0.0% |
| 2017 Q3 | -21.88 Million AUD | 22.78% |
| 2016 Q3 | -28.59 Million AUD | 1.6% |
| 2016 Q4 | -28.59 Million AUD | 0.0% |
| 2016 FY | -28.59 Million AUD | 18.09% |
| 2016 Q2 | -29.05 Million AUD | 0.0% |
| 2016 Q1 | -29.05 Million AUD | 16.76% |
| 2015 Q2 | -29.05 Million AUD | 0.0% |
| 2015 Q3 | -34.9 Million AUD | -20.16% |
| 2015 FY | -34.9 Million AUD | -2.17% |
| 2015 Q4 | -34.9 Million AUD | 0.0% |
| 2015 Q1 | -29.05 Million AUD | 14.97% |
| 2014 Q3 | -34.16 Million AUD | -85.08% |
| 2014 Q2 | -18.46 Million AUD | 4.35% |
| 2014 Q4 | -34.16 Million AUD | 0.0% |
| 2014 FY | -34.16 Million AUD | -172.37% |
| 2014 Q1 | -19.3 Million AUD | -53.86% |
| 2013 Q3 | -13.34 Million AUD | -50.95% |
| 2013 FY | -12.54 Million AUD | -135.02% |
| 2013 Q4 | -12.54 Million AUD | 6.01% |
| 2013 Q2 | -8.84 Million AUD | 0.0% |
| 2013 Q1 | -8.84 Million AUD | -65.66% |
| 2012 FY | -5.33 Million AUD | 37.59% |
| 2012 Q4 | -5.33 Million AUD | 0.0% |
| 2012 Q2 | -6.74 Million AUD | 0.0% |
| 2011 Q2 | -2.88 Million AUD | 0.0% |
| 2011 FY | -8.55 Million AUD | -63.61% |
| 2011 Q4 | -8.54 Million AUD | 0.0% |
| 2010 Q2 | -8.37 Million AUD | 0.0% |
| 2010 FY | -5.22 Million AUD | -21.42% |
| 2010 Q4 | -5.22 Million AUD | 0.0% |
| 2009 Q4 | -4.3 Million AUD | 0.0% |
| 2009 FY | -4.3 Million AUD | 61.71% |
| 2009 Q2 | -7.85 Million AUD | 0.0% |
| 2008 Q2 | -9.17 Million AUD | 0.0% |
| 2008 Q4 | -11.24 Million AUD | 0.0% |
| 2008 FY | -11.24 Million AUD | -51.78% |
| 2007 Q2 | -11.54 Million AUD | 0.0% |
| 2007 Q4 | -7.4 Million AUD | 0.0% |
| 2007 FY | -7.4 Million AUD | 26.07% |
| 2006 Q2 | -15.71 Million AUD | 0.0% |
| 2006 FY | -10.01 Million AUD | 53.1% |
| 2006 Q4 | -10.01 Million AUD | 0.0% |
| 2005 Q4 | -21.36 Million AUD | 0.0% |
| 2005 Q2 | -26.93 Million AUD | 0.0% |
| 2005 FY | -21.36 Million AUD | 27.33% |
| 2004 FY | -29.4 Million AUD | -751.33% |
| 2004 Q4 | -29.4 Million AUD | 0.0% |
| 2004 Q2 | -5.61 Million AUD | 0.0% |
| 2003 Q4 | -3.45 Million AUD | 0.0% |
| 2003 FY | -3.45 Million AUD | 3.72% |
| 2003 Q2 | -1.44 Million AUD | 0.0% |
| 2002 FY | -3.58 Million AUD | 47.67% |
| 2001 FY | -6.85 Million AUD | -53.37% |
| 2000 FY | -4.46 Million AUD | -22347845.0% |
| 1999 FY | -20.00 AUD | 0.0% |
| 1998 FY | -20.00 AUD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AdAlta Limited | -845.17 Thousand AUD | -1376.602% |
| Acrux Limited | -1.45 Million AUD | -755.956% |
| Amplia Therapeutics Limited | -1.82 Million AUD | -584.355% |
| Biome Australia Limited | -1.56 Million AUD | -698.553% |
| BTC Health Limited | -2.02 Million AUD | -517.155% |
| Chimeric Therapeutics Limited | -3.05 Million AUD | -308.773% |
| CSL Limited | 15.76 Billion AUD | 100.079% |
| Clarity Pharmaceuticals Ltd | -136.5 Million AUD | 90.858% |
| Clinuvel Pharmaceuticals Limited | -182.98 Million AUD | 93.18% |
| Noxopharm Limited | -2.31 Million AUD | -437.941% |
| PharmAust Limited | -9.71 Million AUD | -28.471% |
| Proteomics International Laboratories Limited | -6.32 Million AUD | -97.346% |
| Prescient Therapeutics Limited | -10.16 Million AUD | -22.8% |
| PYC Therapeutics Limited | -65.76 Million AUD | 81.023% |
| Race Oncology Limited | -17.18 Million AUD | 27.396% |
| Starpharma Holdings Limited | -19.83 Million AUD | 37.072% |
| EZZ Life Science Holdings Limited | -18.89 Million AUD | 33.965% |
| Botanix Pharmaceuticals Limited | -79.3 Million AUD | 84.264% |
| Memphasys Limited | 4.13 Million AUD | 401.783% |
| Nyrada Inc. | -4.76 Million AUD | -161.666% |
| Anatara Lifesciences Ltd | -982.1 Thousand AUD | -1170.721% |
| Telix Pharmaceuticals Limited | -105.79 Million AUD | 88.203% |
| Bio-Gene Technology Limited | -709.55 Thousand AUD | -1658.819% |
| Zelira Therapeutics Limited | 5.06 Million AUD | 346.28% |
| Patrys Limited | -2.24 Million AUD | -456.971% |
| Dimerix Limited | -21.99 Million AUD | 43.252% |
| Neuren Pharmaceuticals Limited | -17.09 Million AUD | 26.993% |
| Orthocell Limited | -19.92 Million AUD | 37.365% |
| Imugene Limited | -91.56 Million AUD | 86.37% |
| Cynata Therapeutics Limited | -6.2 Million AUD | -101.112% |
| Immutep Limited | -122.18 Million AUD | 89.786% |
| Arovella Therapeutics Limited | -12.71 Million AUD | 1.845% |
| Nanollose Limited | -96.22 Thousand AUD | -12869.436% |
| Invex Therapeutics Ltd | -6.02 Million AUD | -107.132% |
| NeuroScientific Biopharmaceuticals Limited | -4.95 Million AUD | -151.907% |
| Island Pharmaceuticals Limited | -1.23 Million AUD | -907.732% |
| Biotron Limited | -386.06 Thousand AUD | -3132.55% |
| Radiopharm Theranostics Limited | -18.57 Million AUD | 32.814% |
| Tissue Repair Ltd | -16.44 Million AUD | 24.093% |
| AnteoTech Limited | -5 Million AUD | -149.521% |
| Hexima Limited | -2.22 Million AUD | -460.586% |
| Paradigm Biopharmaceuticals Limited | -17.58 Million AUD | 29.017% |
| Recce Pharmaceuticals Ltd | -3.39 Million AUD | -267.472% |
| Avecho Biotechnology Limited | -5.32 Million AUD | -134.177% |
| Actinogen Medical Limited | -9.13 Million AUD | -36.666% |
| Immuron Limited | -11.48 Million AUD | -8.673% |
| Argenica Therapeutics Limited | -15.91 Million AUD | 21.573% |